## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

### This Drug Coverage Decision supersedes the Drug Coverage Decision for the drugs and indications dated March 21, 2017

<table>
<thead>
<tr>
<th>Drug</th>
<th>daclatasvir</th>
<th>elbasvir-grazoprevir</th>
<th>ledipasvir-sofosbuvir</th>
<th>sofosbuvir-velpatasvir</th>
<th>sofosbuvir-velpatasvir-voxilaprevir</th>
<th>Sofosbuvir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Daklinza®</td>
<td>Zepatier®</td>
<td>Harvoni®</td>
<td>Epclusa™</td>
<td>Vosevi™</td>
<td>Sovaldi®</td>
</tr>
<tr>
<td>Dosage Form(s)</td>
<td>30 mg and 60 mg tablets</td>
<td>50 mg/100 mg tablet</td>
<td>90 mg/400 mg tablet</td>
<td>400 mg/100 mg tablet</td>
<td>400 mg/100 mg tablet</td>
<td>400 mg tablet</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Bristol-Myers Squibb Canada</td>
<td>Merck Canada Inc.</td>
<td>Gilead Sciences Canada Inc.</td>
<td>Gilead Sciences Canada Inc.</td>
<td>Gilead Sciences Canada Inc.</td>
<td>Gilead Sciences Canada Inc.</td>
</tr>
<tr>
<td>Submission Type</td>
<td>New submission for Vosevi</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use Reviewed</td>
<td>chronic hepatitis C (CHC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common Drug Review (CDR)</td>
<td>Yes, CDR recommended: to Reimburse with clinical criteria and/or conditions. Visit the CDR website for more details: <a href="http://www.cadth.ca/node/88649">www.cadth.ca/node/88649</a>.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Coverage Decision</td>
<td>Limited Coverage Benefit. Access the criteria from <a href="http://www.gov.bc.ca/pharmacarespecialauthority">www.gov.bc.ca/pharmacarespecialauthority</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>March 13, 2018 (This supersedes the listings decisions for the drugs and indications dated March 21, 2017).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Reason(s)          | • Zepatier, Daklinza, Harvoni, Epclusa, Vosevi and Sovaldi were reviewed by the CDR and received recommendations to reimburse with criteria and conditions, including price reductions.  
• Based on the clinical data reviewed by the CDR, the new all-oral, direct-acting antivirals (DAA) treatments have high cure rates, are better tolerated and are easier and more convenient for patients due to shorter course treatments compared with longer course injectable treatments.  
• Vosevi is a pan-genotypic (treating all virus strains) DAA regimen providing an unmet medical need for patients who had previously received DAA antiviral drugs (i.e., DAA-experienced patients) and has been shown to achieve high cure rates in two randomized controlled trials reviewed by the CDR.  
• BC participated in the pan-Canadian Pharmaceutical Alliance (pCPA) negotiations that concluded agreements with three drug manufacturers, Bristol Myers Squibb Canada, Gilead Sciences Canada Inc. and Merck Canada Inc.  
• Effective March 13, 2018, PharmaCare is expanding the criteria to provide coverage to more patients living with hepatitis C, regardless of the type or severity of their disease. PharmaCare covers treatment-naïve or treatment-experienced adults with CHC genotype 1, 2, 3, 4, 5, 6 or mixed genotype who have liver fibrosis stage F0 or greater (Metavir scale or equivalent) including decompensated cirrhosis (This expanded coverage criteria will... |
supersede the coverage criteria dated March 21, 2017).

- Also effective **March 13, 2018**, PharmaCare covers Vosevi for the treatment of DAA-experienced patients including:
  - NS5A Inhibitor treatment-experienced adult patients with CHC genotype 1, 2, 3, 4, 5 or 6 infection, or
  - Non-NS5A Inhibitor, sofosbuvir-containing regimen treatment-experienced adult patients with CHC genotype 1, 2, 3, or 4 infection

| Other Information | None |

---

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the **Drug Benefit Council (DBC)** gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the **Common Drug Review (CDR)**
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.